Avadel Pharmaceuticals — Q2 2025 Earnings Presentation
25 slides from Avadel Pharmaceuticals's earnings presentation, Aug 7, 2025
Slide 1: Avadel Pharmaceuticals plc
AVADEL Pharmaceuticals plc (NASDAQ: AVDL)
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, obje
Slide 3: A Biopharmaceutical Company Focused on Transforming Medicines to Transform Lives
A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES 3
Slide 4: Strong and Experienced Management Team and Board with Proven Success
Strong and Experienced Management Team and Board Of Directors with Proven Success Recognizing and Unlocking Value Delivered a once-nightly treatment option for patients with narcolepsy, a Clinical drug class that hasn’t experienced significant medical innovation in over 20 years Navigated two approv
Slide 5: AVDL at a glance
>$300M Revenue Since Launch* Corporate Headquarters Publicly traded on Dublin, Ireland NASDAQ since 1996 : AVDL ~3,100 Patients on therapy* St. Louis, US Operations Missouri Wholly-owned pipeline with expansion Management team with extensive opportunities commercial experience in rare and 31 Orange
Slide 6: LUMRYZ development and approval timeline
July 2024 June 2023 First patient dosed in Phase 3 LUMRYZ REVITALYZ trial assessing LUMRYZ for (sodium oxybate) the treatment of idiopathic 2018-2019 2021-2022 Extended-Release hypersomnia Focused development Initiated and completed Oral Suspension efforts on LUMRYZ for RESTORE open-label launched t
Slide 7: Advancing Innovative and Transformative Sleep Medicine Pipeline
Advancing Innovative and Transformative Sleep Medicine Pipeline REGULATORY PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL MAJOR MILESTONES REVIEW Narcolepsy – Excessive Daytime Received FDA approval Sleepiness (EDS) and ODE in May 2023; and/or Cataplexy in launched in June 2023 Ad
Slide 8: Oxybates are the only class of drugs that addresses all 3 symptoms of narcolepsy
In narcolepsy, the body cannot separate wake and sleep – they blend together. Key symptoms include the following: 1. Excessive daytime sleepiness (EDS), pathological sleepiness during the day. 2. Cataplexy, the sudden onset of weak or paralyzed muscles, usually brought on by strong emotions or certa
Slide 9: LUMRYZ's Market Opportunity in Narcolepsy is >50K Patients
LUMRYZ's Market Opportunity in Narcolepsy is >50K Patients >14K patients currently treated Over 50K oxybate-eligible >14,000 patients with first-generation patients with narcolepsy oxybates 25,000+ >50,000 >15K patients who discontinued first- Oxybate market potential patients patients of +$5B1 gene
Slide 10: >25,000 Eligible patients have never started an oxybate
Of eligible patients state middle-of-the-night ~40% dosing is one of the main reasons they have not tried a twice-nightly oxybate >25,000 Eligible patients have never started an oxybate Of providers who have never prescribed an oxybate agree that middle-of-the-night dosing >90% is a challenge for pa
Slide 11: ~65% of Patients with Narcolepsy Experience Poor, Fragmented Sleep
~65% of Patients with Narcolepsy Experience Poor, Fragmented Sleep in Addition to their Daytime Symptoms, Despite Getting Adequate Rest SLEEP CON SOLIDATION ASLEEP AWAKE ASLEEP AWAKE NORMAL NARCOLEPSY 11
Slide 12: Once-Nightly Dosing is a Significant Differentiator Vs. First-Generation Oxybates
Once-Nightly Dosing is a Significant Differentiator Vs. First-Generation Oxybates 80 Maximum concentration 70 of LUMRYZ GHB Concentration, µg/mL (mean ± SE) 60 Granted Orphan Drug Exclusivity in 50 adults and pediatric patients seven 40 years of age and older with narcolepsy 30 based on FDA’s determ
Slide 13: Launch to Date
Launch to Date1 >$300 Net revenue ($M) ~3,100 Patients on therapy Since its launch in June 2023, LUMRYZ has seen Of patients on therapy consistent patient uptake are switch patients >50% from first-generation oxybates 1) Figures as of June 30, 2025 13
Slide 14: LUMRYZ Market Position and 2025 Key Launch Priorities
LUMRYZ Market Position and 2025 Key Launch Priorities
Slide 15: 2025 Priorities Focused on Enrollment and Pull Through Accelerators
2 Years Post-launch, LUMRYZ Has Gained a Strong Market Position with Significant Momentum And Opportunities To Accelerate Growth Broad and Growing Writer Base Adopting across all patient types – switch, new to oxybate, previously discontinued oxybate Executing Market-Leading Office and Patient Servi
Slide 16: Increasing Investments in Salesforce, Direct-to-Patient and HCP Marketing
Increasing Investments in Salesforce, Direct-to-Patient and HCP Marketing and Field Reimbursement Teams to Drive Patient Uptake and Market Expansion Leverage LUMRYZ’s value Achieve market leadership Increase reimbursed proposition to grow in the new to brand patient mix to 80% and switch and total p
Slide 17: Targeted and Early Intervention is Crucial in Addressing Patient Persistency
Targeted and Early Intervention is Crucial in Addressing the Historic Challenges of Patient Persistency Seen with Oxybates Doubled nursing team at our patient services center allowing for more frequent/tailored patient Improving LUMRYZ interventions Persistency Can Have an Increased our field suppor
Slide 18: >90% of Commercial Lives Covered; Contracts with All Three PBM-Owned GPOs
Of Commercial Lives Covered; >90% Contracts in Place with All Three PBM-Owned GPOs Essential access and affordability programs ✓ $0 commercial copay program ✓ Patient assistance program ✓ Temporary assistance program All patients have access Personalized support for patients and offices to patient s
Slide 19: LUMRYZ Expansion Opportunities
LUMRYZ Expansion Opportunities
Slide 20: Idiopathic hypersomnia opportunity and REVITALYZ Phase 3 trial
Idiopathic hypersomnia (IH) is a rare sleep disorder characterized by excessive daytime sleepiness (EDS) not attributable to any other ~11% treated medical conditions; 42,000 patients with the only FDA diagnosed with IH in US approved oxybate treatment Initiated REVITALYZ Phase 3 trial to evaluate t
Slide 21: A Leader in the Sleep Space With Substantial Growth Opportunities
A Leader in the Sleep Space With Substantial Growth Opportunities Meeting Unmet Needs in Narcolepsy 94%1 of patients prefer LUMRYZ over first-generation oxybates due to once at night dosing; awarded Orphan Drug Exclusivity for major contribution to patient care Opportunity For Growth In Narcolepsy $
Slide 22: Financials
Financials
Slide 23: Financial Summary
Financial Summary1 Q2 YTD ($ in millions) 2025 2024 2025 2024 Product Revenue $68.1 $41.5 $120.6 $68.7 Operating Expenses $52.9 $51.5 $102.8 $103.1 Operating Income $8.9 ($12.7) $5.9 ($38.8) (Loss) Cash, Cash Equivalents & Marketable $81.5 $71.4 $81.5 $71.4 Securities 1 – Refer to Forms 10-Q for the
Slide 24: GAAP vs. Non-GAAP Reconciliation
GAAP vs. Non-GAAP Reconciliation Q2 YTD ($ in millions) 2025 2024 2025 2024 GAAP Operating Income (Loss) $8.9 ($12.7) $5.9 ($38.8) Stock Based Compensation $5.3 $5.5 $9.5 $10.9 Depreciation & Amortization 1 $0.8 $1.0 $1.5 $2.1 Transaction Costs 2 $- $5.0 $- $5.5 Non-GAAP Operating Income (Loss) $15.
Slide 25: Join us on our transformational journey
Join us on our transformational journey 25
Avadel Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix